首页> 美国卫生研究院文献>PLoS Clinical Trials >Interaction of Rio1 Kinase with Toyocamycin Reveals a Conformational Switch That Controls Oligomeric State and Catalytic Activity
【2h】

Interaction of Rio1 Kinase with Toyocamycin Reveals a Conformational Switch That Controls Oligomeric State and Catalytic Activity

机译:Rio1激酶与Toyocamycin的相互作用揭示了控制寡聚状态和催化活性的构象转换。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Rio1 kinase is an essential ribosome-processing factor required for proper maturation of 40 S ribosomal subunit. Although its structure is known, several questions regarding its functional remain to be addressed. We report that both Archaeoglobus fulgidus and human Rio1 bind more tightly to an adenosine analog, toyocamycin, than to ATP. Toyocamycin has antibiotic, antiviral and cytotoxic properties, and is known to inhibit ribosome biogenesis, specifically the maturation of 40 S. We determined the X-ray crystal structure of toyocamycin bound to Rio1 at 2.0 Å and demonstrated that toyocamycin binds in the ATP binding pocket of the protein. Despite this, measured steady state kinetics were inconsistent with strict competitive inhibition by toyocamycin. In analyzing this interaction, we discovered that Rio1 is capable of accessing multiple distinct oligomeric states and that toyocamycin may inhibit Rio1 by stabilizing a less catalytically active oligomer. We also present evidence of substrate inhibition by high concentrations of ATP for both archaeal and human Rio1. Oligomeric state studies show both proteins access a higher order oligomeric state in the presence of ATP. The study revealed that autophosphorylation by Rio1 reduces oligomer formation and promotes monomerization, resulting in the most active species. Taken together, these results suggest the activity of Rio1 may be modulated by regulating its oligomerization properties in a conserved mechanism, identifies the first ribosome processing target of toyocamycin and presents the first small molecule inhibitor of Rio1 kinase activity.
机译:Rio1激酶是40 S核糖体亚基正确成熟所需的必需核糖体加工因子。尽管其结构是已知的,但有关其功能的几个问题仍有待解决。我们报道古细菌和人类Rio1都更紧密地结合到腺苷类似物toyocamycin,而不是ATP。丰卡霉素具有抗生素,抗病毒和细胞毒性特性,并已知能抑制核糖体的生物发生,特别是40 S的成熟。我们确定了丰卡霉素的X射线晶体结构在2.0Å处与Rio1结合,并证明了丰卡霉素在ATP结合口袋中结合蛋白质。尽管如此,测得的稳态动力学与玩具霉素严格的竞争抑制作用不一致。在分析这种相互作用时,我们发现Rio1能够进入多个不同的寡聚状态,而Toyocamycin可能通过稳定催化活性较低的寡聚物来抑制Rio1。我们还提出了古细菌和人Rio1均受高浓度ATP抑制底物的证据。寡聚态研究表明,两种蛋白质在ATP存在下都会进入更高阶的寡聚态。研究表明,Rio1的自磷酸化作用减少了低聚物的形成并促进了单体化作用,从而形成了最活跃的物种。综上所述,这些结果表明,Rio1的活性可以通过保守机制调节寡聚化特性来调节,确定了丰卡霉素的第一个核糖体加工靶标,并提出了Rio1激酶活性的第一个小分子抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号